Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries.

@article{Jdar2003MeningococcalCV,
  title={Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries.},
  author={Luis J{\'o}dar and F Marc Laforce and Costante Ceccarini and Teresa Aguado and Dan M Granoff},
  journal={Lancet},
  year={2003},
  volume={361 9372},
  pages={1902-4}
}
VIEWPOINT There are major disparities in drug and vaccine development for diseases that mainly affect the developing world, as opposed to those that affect industrialised nations. From the time of introduction of a new vaccine in Europe or the USA, the adoption of these vaccines in developing countries takes a decade or more. 1 For example, hepatitis B vaccine and Haemophilus influenzae type b conjugate vaccines have been used routinely for over 10 years in North America and in most European… CONTINUE READING